Toru Wakamatsu1,2, Shigeki Kakunaga3, Satoshi Takenaka1, Hidetatsu Outani1, Kenichiro Hamada1, Yoshinori Imura1,2, Yumiko Hori4, Norifumi Naka1,2, Ikuo Kudawara3, Hideki Yoshikawa1, Takafumi Ueda5. 1. Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. 2. Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan. 3. Department of Orthopaedic Surgery, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan. 4. Department of Pathology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. 5. Department of Orthopaedic Surgery, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan. ueda.takafumi.ah@mail.hosp.go.jp.
Abstract
BACKGROUND: Extraskeletal osteosarcoma (ESOS) is an extremely rare soft tissue sarcoma. Their prognosis remains poor. Our purposes were to identify the effective chemotherapeutic regimen for ESOS. METHODS: We retrospectively reviewed 16 patients with ESOS treated at the Osaka University Orthopaedic Oncology Group between 1992 and 2012. We extracted the clinical data on patients. Kaplan-Meier method and the log-rank test were used for survival analyses. RESULTS: Median age of the patients was 61.5 years (range 25-79 years). Wide local excision was performed for 11 patients and 9 patients were treated combined with chemotherapy. The 5-year disease-specific survival (DSS) rate was 53.9%. The 5-year DSS rates for patients treated with adjuvant/neoadjuvant chemotherapy or not were 66.7% or 25%, respectively (p = 0.0215). Furthermore, the 5-year DSS rates for patients treated with adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide and those treated with other regimens were 100% or 40%, respectively (p = 0.0327). CONCLUSION: The present study demonstrated that adjuvant/neoadjuvant chemotherapy, especially consisting of doxorubicin and ifosfamide, was potentially efficacious for ESOS. Further prospective study using this multimodality treatment approach to patients with ESOS should be strongly warranted.
BACKGROUND: Extraskeletal osteosarcoma (ESOS) is an extremely rare soft tissue sarcoma. Their prognosis remains poor. Our purposes were to identify the effective chemotherapeutic regimen for ESOS. METHODS: We retrospectively reviewed 16 patients with ESOS treated at the Osaka University Orthopaedic Oncology Group between 1992 and 2012. We extracted the clinical data on patients. Kaplan-Meier method and the log-rank test were used for survival analyses. RESULTS: Median age of the patients was 61.5 years (range 25-79 years). Wide local excision was performed for 11 patients and 9 patients were treated combined with chemotherapy. The 5-year disease-specific survival (DSS) rate was 53.9%. The 5-year DSS rates for patients treated with adjuvant/neoadjuvant chemotherapy or not were 66.7% or 25%, respectively (p = 0.0215). Furthermore, the 5-year DSS rates for patients treated with adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide and those treated with other regimens were 100% or 40%, respectively (p = 0.0327). CONCLUSION: The present study demonstrated that adjuvant/neoadjuvant chemotherapy, especially consisting of doxorubicin and ifosfamide, was potentially efficacious for ESOS. Further prospective study using this multimodality treatment approach to patients with ESOS should be strongly warranted.
Authors: Syed A Ahmad; Shreyaskumar R Patel; Matthew T Ballo; Treneth P Baker; Alan W Yasko; Xuemei Wang; Barry W Feig; Kelly K Hunt; Patrick P Lin; Kristen L Weber; Lei L Chen; Gunar K Zagars; Raphael E Pollock; Robert S Benjamin; Peter W T Pisters Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: A Longhi; S S Bielack; R Grimer; J Whelan; R Windhager; A Leithner; A Gronchi; D Biau; P Jutte; A H Krieg; F M Klenke; G Grignani; D M Donati; R Capanna; J Casanova; C Gerrand; G Bisogno; S Hecker-Nolting; M De Lisa; L D'Ambrosio; M Willegger; G Scoccianti; S Ferrari Journal: Eur J Cancer Date: 2017-02-03 Impact factor: 9.162
Authors: Zhengfu Fan; Shreyaskumar Patel; Valerae O Lewis; B Ashleigh Guadagnolo; Patrick P Lin Journal: Clin Orthop Relat Res Date: 2015-07-22 Impact factor: 4.176
Authors: Sing Yu Goldstein-Jackson; Georg Gosheger; Günter Delling; Wolfgang E Berdel; G Ulrich Exner; Gernot Jundt; Jan-Nicolas Machatschek; Andreas Zoubek; Heribert Jürgens; Stefan S Bielack Journal: J Cancer Res Clin Oncol Date: 2005-05-26 Impact factor: 4.553
Authors: Terence T Sio; Charles C Vu; Schoeb Sohawon; Paul Van Houtte; Juliette Thariat; Paul J Novotny; Robert C Miller; Gil Bar-Sela Journal: Am J Clin Oncol Date: 2016-02 Impact factor: 2.339